Unknown

Dataset Information

Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.


ABSTRACT: Genomic characterization of cancer has enabled identification of numerous molecular targets, which has led to significant advances in personalized medicine. However, with few exceptions, precision medicine approaches in the plasma cell malignancy multiple myeloma (MM) have had limited success, likely owing to the subclonal nature of molecular targets in this disease. Targeted therapies against FGFR3 have been under development for the past decade in the hopes of targeting aberrant FGFR3 activity in MM. FGFR3 activation results from the recurrent transforming event of t(4;14) found in ∼15% of MM patients, as well as secondary FGFR3 mutations in this subgroup. To evaluate the effectiveness of targeting FGFR3 in MM, we undertook a phase 2 clinical trial evaluating the small-molecule FG

SUBMITTER: Croucher DC 

PROVIDER: S-EPMC10240837 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature